Literature DB >> 17980660

Epidemiology of multi-drug-resistant gram-negative bacteria: data from an university hospital over a 36-month period.

Ralf-Peter Vonberg1, Anneke Wolter, Iris F Chaberny, Axel Kola, Stefan Ziesing, Sebastian Suerbaum, Petra Gastmeier.   

Abstract

Multi-drug-resistant gram-negative rods (MRGN) are associated with increased morbidity and mortality. Little is known about the epidemiology of this group of pathogens in endemic situations. The aim of this study was to determine the epidemiology of MRGN in our facility during a 3-year period. Prospective surveillance of any patient colonized or infected with a MRGN during hospital stay from 2002 to 2004 was performed. Patients proven to harbour extended beta-lactamase (ESBL)-producing bacteria as well as cystic fibrosis (CF) patients were excluded. After culture of MRGN, patients were considered positive until three consecutive samples from all previously affected locations had been tested negative. Five hundred and three case-patients were enrolled accounting for 8081 isolation days and an incidence of 0.43 per 1000 patient days with an average length of stay of 37.5 days (average duration of isolation: 22.6 days). Sixty-six percent of case-patients were known to be positive at the time of admission. Fifty-one percent of MRGN were acquired within the hospital. The most frequently detected species was Pseudomonas aeruginosa. There were 108 case-patients with pan-resistant pathogens. Eight of 169 (4.7%) screened contact patients were found to be MRGN positive. In our hospital cross-transmission of MRGN seems to occur less frequently than cross-transmission of MRSA (9.0%) or ESBL (11.1%). To prevent nosocomial transmission it is recommended to isolate patients colonized or infected with MRGN in our hospital in single rooms. Because there are many immunocompromised patients in our facility we will continue our current infection control management until more data concerning MRGN are available.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17980660     DOI: 10.1016/j.ijheh.2007.08.008

Source DB:  PubMed          Journal:  Int J Hyg Environ Health        ISSN: 1438-4639            Impact factor:   5.840


  6 in total

Review 1.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

2.  [Management of multiresistant pathogens in urology].

Authors:  G Magistro; C Gratzke; C G Stief; W Weidner; F Wagenlehner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

3.  The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit.

Authors:  J Kristie Johnson; Gwen Smith; Mary S Lee; Richard A Venezia; O Colin Stine; James P Nataro; William Hsiao; Anthony D Harris
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

4.  Trends in the annual incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a 8-year retrospective study in a large teaching hospital in northern Italy.

Authors:  Cristiano Alicino; Daniele Roberto Giacobbe; Andrea Orsi; Federico Tassinari; Cecilia Trucchi; Giovanni Sarteschi; Francesco Copello; Valerio Del Bono; Claudio Viscoli; Giancarlo Icardi
Journal:  BMC Infect Dis       Date:  2015-10-13       Impact factor: 3.090

5.  Carriage of multidrug-resistant bacteria among pediatric patients before and during their hospitalization in a tertiary pediatric unit in Tunisia.

Authors:  Miniar Tfifha; Asma Ferjani; Manel Mallouli; Nesrine Mlika; Saoussen Abroug; Jalel Boukadida
Journal:  Libyan J Med       Date:  2018-12       Impact factor: 1.657

6.  Efficacy of surface disinfectant cleaners against emerging highly resistant gram-negative bacteria.

Authors:  Mirja Reichel; Anastasija Schlicht; Christiane Ostermeyer; Günter Kampf
Journal:  BMC Infect Dis       Date:  2014-05-28       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.